NRx Research Pipeline
Our pipeline includes medicinal candidates in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Distress (ARDS) in partnership with Relief Therapeutics, AG, and the first drug in development to treat Bipolar Depression in Patients with Acute Suicidality.
Study Sponsored by National Institute of Health | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Study Sponsored By The National Institute of Health | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19
BriLife™ Covid 19 Vaccine
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. (BRILIFE002)
Bipolar Depression | Suicidal ideation
with Acute suicidal ideation
Sequential Therapy for the Treatment of Severe Bipolar Depression.
with Acute suicial ideation
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
(ASIB) in Bipolar Depression
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
NRX101 for Moderate Bipolar Depression and Suicidal Ideation